1 Min Read
Feb 13 (Reuters) - Trovagene Inc:
* TROVAGENE ANNOUNCES ACTIVATION OF TWO ADDITIONAL CLINICAL TRIAL SITES TO CONDUCT ITS PHASE 1B/2 STUDY OF PCM-075 IN PATIENTS WITH AML Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.